As a companion diagnostic, Oncomine will be used to identify patients eligible for treatment with Servier’s Voranigo.

Driving the news: The drug, called Voranigo, is the result of collaborative research done by 83-year-old Duke ...

Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent™ Oncomine™ Dx Target Test as a companion ...

The IDH1/2 inhibitor, which can be dosed orally and is designed to cross the blood-brain barrier into the central nervous system, is being marketed as Voranigo for patients aged 12 years and older ...

The newly FDA-approved brain cancer therapy Voranigo (vorasidenib) has its roots in North Carolina. It is the product of research by Duke University's Darell Bigner and Bert Vogelstein of Johns ...

But after 33 rounds of radiotherapy and 12 rounds of chemotherapy she was handed a lifeline when she qualified to trial a new drug. Vorasidenib, or Voranigo, specifically treats brain and spinal ...

Royalty Pharma PLC (RPRX) reports robust growth in Portfolio Receipts and raises full-year guidance, while navigating potential market challenges.

The FDA has approved Thermo Fisher’s Oncomine Dx Target Test, a next-generation sequencing based companion diagnostic, to ...

The brain cancer therapy recently approved by the FDA, Voranigo (vorasidenib), was developed from research by Duke University’s Darell Bigner and Johns Hopkins University's Bert Vogelstein and ...